Overall, these results indicate that PD-1/PD-L1 inhibitors have limited single-agent efficacy in GCB lymphomas, but there remains significant clinical potential when combined with other therapies, including epigenetic modulators and agents targeting tumor metabolism, as discussed below. This evidence concerns the gene PDCD1 and lymphoma.